Literature DB >> 21512165

Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.

Alain Stepanian1, Marie Cohen-Moatti, Thibaut Sanglier, Paulette Legendre, Nejma Ameziane, Vassilis Tsatsaris, Laurent Mandelbrot, Dominique de Prost, Agnès Veyradier.   

Abstract

OBJECTIVE: The goal of this study was to search for an association between a desintegrin-like and metalloprotease thrombospondin type 1 motif, member 13 (ADAMTS13) levels and the occurrence of preeclampsia, its characteristics (time-onset and severity), and its consequences (occurrence of fetal growth restriction or preterm delivery). METHODS AND
RESULTS: We studied 140 pairs of women in a case-control study with 3 matching criteria: maternal age, gestational age, and ethnic origin. We measured ADAMTS13 activity using a fluorescence resonance energy transfer assay with the fluorescence resonance energy transfer-VWF73 peptide. ELISA was used to assess protein antigen levels: ADAMTS13, von Willebrand Factor (VWF), interleukin-6, C-reactive protein, P-selectin, and thrombospondin-1. The lowest levels of ADAMTS13 (activity ≤ 70% or antigen ≤ 592 ng/mL) were significantly associated with preeclampsia (odds ratios [OR] [95% confidence interval] of 4.2 [1.1 to 15] and 14.3 [1.7 to 123], respectively). This association was independent of VWF levels and preeclampsia risk factors but dependent on interleukin-6 and C-reactive protein levels for ADAMTS13 activity. Levels of ADAMTS13 activity (≤ 57%) were significantly associated with early-onset preeclampsia (OR = 2.5 [1.1 to 5.8]). Severe preeclampsia was associated with the highest levels of P-selectin (>57 ng/mL) (OR = 3.4 [1.2 to 9.7]).
CONCLUSIONS: Preeclampsia is associated with decreased levels of ADAMTS13, independently of VWF. This decrease is quantitative, occurs early, and seems to be dependent on inflammation. Our results suggest that ADAMTS13 could participate in the pathophysiology of preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512165     DOI: 10.1161/ATVBAHA.111.223610

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

1.  Endothelial Dysfunction: The Secret Agent Driving Kidney Disease.

Authors:  Richard J Johnson; Masaomi Nangaku
Journal:  J Am Soc Nephrol       Date:  2015-06-02       Impact factor: 10.121

2.  ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.

Authors:  Luise Erpenbeck; Melanie Demers; Zsuzsanna K Zsengellér; Maureen Gallant; Stephen M Cifuni; Isaac E Stillman; S Ananth Karumanchi; Denisa D Wagner
Journal:  J Am Soc Nephrol       Date:  2015-06-02       Impact factor: 10.121

3.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 4.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 5.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

6.  Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.

Authors:  Juan Xiao; Yun Feng; Xueyin Li; Wei Li; Lei Fan; Jing Liu; Xue Zeng; Kaiyue Chen; Xi Chen; Xiaoshui Zhou; X Long Zheng; Suhua Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-27       Impact factor: 8.311

7.  Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.

Authors:  Juan Xiao; Sheng-Yu Jin; Jing Xue; Nicoletta Sorvillo; Jan Voorberg; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-28       Impact factor: 8.311

8.  Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis.

Authors:  Danyelle R A Rios; Ana Paula Fernandes; Roberta C Figueiredo; Daniela A M Guimarães; Cláudia N Ferreira; Ana C Simões E Silva; Maria G Carvalho; Karina B Gomes; Luci Maria Sant' Ana Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

9.  High frequency of acquired ADAMTS13 deficiency after hemolysis in Hemiscorpius Lepturus (scorpion) stung children.

Authors:  Ehsan Valavi; Ali Ahmadzadeh; Parisa Amoori; Aidin Daneshgar
Journal:  Indian J Pediatr       Date:  2013-07-28       Impact factor: 1.967

10.  Thrombotic microangiopathy associated with use of interferon-beta.

Authors:  Teresa Olea; Raquel Díaz-Mancebo; Maria-Luz Picazo; Jorge Martínez-Ara; Angel Robles; Rafael Selgas
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.